|
|
Article: Zealand, Aventis Enter $100M Pact To Develop Diabetes Drug.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BioWorld International Correspondent
Danish therapeutic peptide specialist Zealand Pharmaceuticals A/S licensed its candidate Type II diabetes treatment ZP10 to Aventis SA in a deal worth up to US$100 million in milestones plus additional royalties on product sales.
The agreement, which includes an up-front payment of US$10 million, assigns global ZP10 rights to Aventis.
The Strasbourg, France-based pharmaceutical firm will take on responsibility for clinical development, regulatory approval, manufacturing, marketing and sales of the product.
This transaction represents Zealand's second deal with a major pharmaceutical firm this year. ...